<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00184821</url>
  </required_header>
  <id_info>
    <org_study_id>QKF03-diab</org_study_id>
    <secondary_id>2004.11.022</secondary_id>
    <nct_id>NCT00184821</nct_id>
  </id_info>
  <brief_title>Ischemic Injury and Ischemic Preconditioning in Diabetes</brief_title>
  <official_title>Acute Local Ischemic Preconditioning in Patients With Type 1 Diabetes in Vivo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Diabetes Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this proof-of-concept study, forearm vulnerability to ischemic exercise is studied in&#xD;
      patients with type 1 diabetes mellitus with and without prior ischemic preconditioning (short&#xD;
      period of ischemia that protects against subsequent ischemic exercise). Annexin A5&#xD;
      scintigraphy is used to quantify subtle signs of mild and reversible forearm injury that&#xD;
      results from ischemic exercise.&#xD;
&#xD;
      The following hypotheses are tested:&#xD;
&#xD;
        1. Patients with type 1 diabetes are not more vulnerable to ischemic injury as compared&#xD;
           with previously studied healthy volunteers.&#xD;
&#xD;
        2. Ischemic preconidtioning is still present in patients with type 1 diabetes. Depending on&#xD;
           the validity of hypothesis 2, the effect of short pharmacological interventions are&#xD;
           studied on vulnerability to forearm ischemia/reperfusion injury in the absence or&#xD;
           presence of local forearm ischemic preconditioning.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients will be studied in supine position after an overnight fast, while plasma glucose&#xD;
      levels are monitored. In the first 8 patients intravenous insulin is administered as needed,&#xD;
      to reach target glucose levels between 5-7 mmol/l. Patients will be subjected to 10 minutes&#xD;
      of forearm ischemia (non-dominant arm), combined with handgripping at 50% of maximal force&#xD;
      until exhaustion. Upon reperfusion, Tc-99m-HYNIC-Annexin A5 will be injected intravenously.&#xD;
      Targeting of annexin A5 to thenar muscle and forearm flexor muscle will be quantified as the&#xD;
      percentage difference in radioactivity between experimental and control side. This procedure&#xD;
      will be performed twice (randomized cross-over design), with at least 2 week interval, either&#xD;
      with or without 10 minutes ischemia followed by 10 minutes of reperfusion prior to ischemic&#xD;
      exercise.&#xD;
&#xD;
      Depending on the results of this study, substudies will be performed to study the effect of&#xD;
      diazoxide (K-ATP channel opener, may mimic ischemic preconditioning), glibenclamide (K-ATP&#xD;
      channel blocker, may inhibit ischemic preconditioning) or adenosine (infusion into brachial&#xD;
      artery of non-dominant arm as a substitute for ischemic preconditioning).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">May 2005</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Defined Population</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <enrollment>20</enrollment>
  <condition>Diabetes Mellitus, Insulin-Dependent</condition>
  <condition>Ischemia-Reperfusion Injury</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ischemic preconditioning</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Forearm ischemic exercise</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Annexin A5 scintigraphy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diazoxide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glibenclamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adenosine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  type 1 diabetes mellitus&#xD;
&#xD;
          -  age 18-50 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hypertension (systolic blood pressure &gt; 140 mmHg and/or diastolic blood pressure &gt; 90&#xD;
             mmHg&#xD;
&#xD;
          -  cardiovascular disease (coronary artery insufficiency,CVA/TIA, peripheral artery&#xD;
             disease&#xD;
&#xD;
          -  HbA1c &gt; 9%&#xD;
&#xD;
          -  Body Mass Index &lt; 25 kg/m2&#xD;
&#xD;
          -  Unable to stop co-medication (other than insulin) for 1 week&#xD;
&#xD;
          -  Previous exposure to radiation (diagnostic or therapeutic) in the past year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Engbersen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Radboud University Nijmegen Medical Centre; department of Pharmacology-Toxicology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerard Rongen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Radboud University Nijmegen Medical Centre; Department of Pharmacology-Toxicology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wim Oyen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Radboud University Nijmegen Medical Centre; Department of Nuclear Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Mol, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Canisius Wilhelmina Ziekenhuis Nijmegen; Department of Internal Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Smits, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University Nijmegen Medical Centre; Department of Pharmacology-Toxicology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>B. Bravenboer, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Catharina Hospital Eindhoven, Dept. of Internal Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Centre Nijmegen; Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>April 4, 2007</last_update_submitted>
  <last_update_submitted_qc>April 4, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2007</last_update_posted>
  <keyword>Diabetes</keyword>
  <keyword>Ischemia</keyword>
  <keyword>Annexin A5 scintigraphy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reperfusion Injury</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glyburide</mesh_term>
    <mesh_term>Adenosine</mesh_term>
    <mesh_term>Diazoxide</mesh_term>
    <mesh_term>Annexin A5</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

